SPAC9E9.17c Antibody

What is SPAC9E9.17c and why is it studied in fission yeast research?

SPAC9E9.17c is a systematic gene identifier in Schizosaccharomyces pombe (fission yeast), which has been identified in several epigenetic studies as having an "Active" chromatin state in quiescent (G0) cells . The protein encoded by this gene appears to be of interest in studies examining chromatin regulation and gene expression during cellular quiescence. Researchers study this gene to understand fundamental mechanisms of gene regulation in eukaryotic systems, particularly as it relates to cell cycle transitions and stress responses.

What experimental applications utilize the SPAC9E9.17c antibody?

The SPAC9E9.17c antibody is primarily used in the following experimental applications:

• Chromatin immunoprecipitation (ChIP) assays to study protein-DNA interactions

• Western blotting for protein expression analysis

• Immunofluorescence to examine cellular localization

• Flow cytometry for quantitative protein expression analysis

These applications are particularly valuable when investigating the role of SPAC9E9.17c in chromatin regulation during quiescence, as indicated by its presence in studies examining active chromatin states in G0 cells .

What sample preparation methods are recommended for optimal SPAC9E9.17c antibody performance?

For optimal antibody performance with S. pombe samples:

• For protein extraction, use either mechanical disruption with glass beads or enzymatic cell wall digestion with zymolyase

• Include protease inhibitors (such as those used in studies with similar fission yeast proteins) to prevent degradation

• For chromatin immunoprecipitation, crosslink with 1% formaldehyde for 15-20 minutes

• When examining quiescent cells, ensure proper isolation protocols are followed as described in studies utilizing similar antibodies in fission yeast

The specific parameters may need optimization depending on the experimental design and the particular strain of S. pombe being utilized.

How can I validate the specificity of SPAC9E9.17c antibody in my experiments?

To validate antibody specificity:

• Include a SPAC9E9.17c deletion strain as a negative control

• Perform peptide competition assays to confirm specific binding

• Utilize western blotting to verify the antibody detects a protein of the expected molecular weight

• Compare immunostaining patterns with published localization data or GFP-tagged versions of the protein

These validation steps are crucial for ensuring reliable experimental results, especially when studying chromatin-associated proteins where cross-reactivity can compromise data interpretation.

How does SPAC9E9.17c function change between vegetative growth and quiescence?

Based on available data, SPAC9E9.17c shows differential chromatin association patterns between vegetative growth and quiescent states. In quiescent cells, SPAC9E9.17c has been identified as having an "Active" chromatin state , suggesting it may play a role in maintaining specific gene expression programs during G0.

Quantitative analysis from transcriptome studies reveals gene expression changes between vegetative and quiescent states. This is consistent with observations of other genes in the same chromosomal region, which show substantial upregulation during quiescence, including:

The significant changes observed in neighboring genes suggest that SPAC9E9.17c may be part of a chromosomal region that undergoes coordinated regulation during the transition to quiescence .

What is the relationship between SPAC9E9.17c and chromatin remodeling complexes like Ino80C?

Research indicates potential functional relationships between SPAC9E9.17c and chromatin remodeling complexes such as Ino80C. The Ino80 chromatin remodeling complex plays an essential role in quiescence, particularly in evicting H2A.Z from chromatin in quiescent cells, thereby inactivating subtelomeric boundary elements .

Given that SPAC9E9.17c shows active chromatin state in quiescent cells, it may interact with or be regulated by chromatin remodeling factors like Ino80C. Researchers investigating this relationship should consider:

• Co-immunoprecipitation experiments to detect physical interactions

• Sequential ChIP (ChIP-reChIP) to identify co-occupancy at specific genomic loci

• Genetic interaction studies using deletion or conditional mutants

• Chromatin accessibility assays (like ATAC-seq) in wild-type versus mutant backgrounds

Understanding these relationships may provide insights into mechanisms of gene regulation during quiescence and stress responses.

What technical challenges might arise when using SPAC9E9.17c antibody in ChIP-seq experiments and how can they be addressed?

ChIP-seq with SPAC9E9.17c antibody may present several technical challenges:

• Cross-reactivity with related proteins: To address this, perform rigorous validation using knockout controls and peptide competition assays. Also consider using epitope-tagged versions of SPAC9E9.17c for comparison.

• Low abundance targets: If SPAC9E9.17c has low expression or transient chromatin association, optimize fixation conditions (varying formaldehyde concentration from 0.75-1.5% and fixation times from 10-30 minutes) and increase starting material.

• Inconsistent immunoprecipitation efficiency: This can be mitigated by testing different antibody lots, optimizing antibody concentration, and including spike-in normalization controls.

• Signal-to-noise issues in genome-wide studies: Implement stringent peak calling parameters and use appropriate controls including input DNA and IgG controls.

• Cell population heterogeneity: When studying quiescent populations, ensure proper synchronization or separation techniques to obtain pure G0 populations, as heterogeneous samples can dilute specific signals.

To validate ChIP-seq results, researchers should confirm selected peaks by ChIP-qPCR and correlate findings with other epigenomic datasets .

How does the epitope accessibility of SPAC9E9.17c change in different experimental conditions?

Epitope accessibility of SPAC9E9.17c may vary significantly depending on:

• Cell cycle phase: Quiescent (G0) versus vegetative cells show different chromatin states, potentially affecting antibody access to SPAC9E9.17c epitopes .

• Chromatin compaction status: The association with active chromatin in quiescent cells suggests that SPAC9E9.17c epitopes might be more accessible in G0 cells compared to other cellular states.

• Protein-protein interactions: Binding partners may mask epitopes, particularly if SPAC9E9.17c interacts with chromatin remodeling complexes like Ino80C .

• Post-translational modifications: Modifications can alter epitope structure or accessibility.

To address variable epitope accessibility:

• Use multiple antibodies targeting different regions of SPAC9E9.17c

• Compare native ChIP with cross-linked ChIP results

• Optimize sonication or nuclease digestion parameters to ensure adequate chromatin fragmentation

• Test different detergent concentrations in extraction buffers to improve epitope exposure while maintaining protein-protein interactions of interest

How can contradictory results between immunoassays be reconciled when studying SPAC9E9.17c?

When faced with contradictory results across different immunoassay platforms:

• Evaluate antibody specificity in each assay context: Similar to observations with other antibodies like anti-C9 autoantibodies , modifications to the target protein (such as alkylation or other structural changes) can dramatically alter epitope recognition. Test whether iodoacetamide treatment or other modifications affect SPAC9E9.17c antibody binding.

• Consider post-translational modifications: Discrepancies might arise from differential detection of modified forms of SPAC9E9.17c. Employ phosphatase or deacetylase treatments to determine if modifications affect antibody recognition.

• Examine buffer and assay conditions: As demonstrated with other antibodies, SPAC9E9.17c epitope recognition may be highly sensitive to specific buffer components, pH, or detergents.

• Use multiple detection methods: Complement antibody-based techniques with mass spectrometry or other label-free methods to resolve contradictions.

• Assess epitope masking: Protein-protein interactions in different cellular contexts may mask epitopes. Consider using epitope-tagged versions of SPAC9E9.17c to compare with antibody-based detection.

What protocols yield optimal results when using SPAC9E9.17c antibody for immunoprecipitation?

For optimal immunoprecipitation with SPAC9E9.17c antibody:

Cell Lysis and Extract Preparation:

• Harvest 50-100 ml of yeast culture (OD600 = 0.5-0.8)

• Wash cells in cold PBS containing protease inhibitors

• Lyse cells using glass bead disruption in lysis buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate)

• Include protease inhibitors, phosphatase inhibitors, and HDAC inhibitors as needed

• Clear lysate by centrifugation (13,000 × g, 15 min, 4°C)

Immunoprecipitation:

• Pre-clear extract with Protein A/G beads (1 hour, 4°C)

• Incubate cleared extract with 2-5 μg SPAC9E9.17c antibody overnight at 4°C

• Add Protein A/G beads and incubate for 2-3 hours at 4°C

• Wash beads 4-5 times with wash buffer (lysis buffer with 500 mM NaCl)

• Elute bound proteins with SDS sample buffer or by competition with specific peptide

This protocol can be adapted from similar approaches used with S. pombe proteins studied in chromatin contexts .

How should researchers approach experimental design when investigating SPAC9E9.17c function during quiescence?

When investigating SPAC9E9.17c function during quiescence:

• Establish reliable quiescence induction protocols:

  • Nitrogen starvation method: Grow cells to mid-log phase, then transfer to EMM without nitrogen

  • Glucose limitation method: Grow cells to saturation in media with limited glucose

  • Stationary phase method: Allow cultures to reach stationary phase naturally

• Confirm quiescence entry:

  • Verify 1C DNA content by flow cytometry (>80% of cells should have 1C DNA content)

  • Assess cell wall thickness and heat resistance

  • Measure transcriptional markers of quiescence

• Experimental approaches:

  • Generate conditional mutants for SPAC9E9.17c to circumvent potential lethality

  • Use rapid induction/repression systems (e.g., thiamine-repressible nmt1 promoter)

  • Perform time-course experiments during quiescence entry and exit

  • Compare SPAC9E9.17c chromatin association patterns with established quiescence-specific factors

• Controls:

  • Include genetic controls (deletion strains) for proper antibody validation

  • Compare SPAC9E9.17c behavior with known quiescence factors (e.g., genes in Table 2 from search result )

  • Use epitope-tagged strains in parallel with antibody-based detection

This experimental approach aligns with studies examining other chromatin factors during quiescence in S. pombe .

What methods can distinguish between specific and non-specific signals when using SPAC9E9.17c antibody?

To distinguish specific from non-specific signals:

• Generate and validate proper controls:

  • Create a SPAC9E9.17c deletion strain as a definitive negative control

  • Use isotype-matched non-specific antibodies in parallel experiments

  • Include peptide competition assays by pre-incubating antibody with blocking peptide

• Employ multiple validation approaches:

  • Compare signals between antibody-based detection and epitope-tagged versions

  • Use orthogonal detection methods (mass spectrometry, RNA expression correlation)

  • Verify expected molecular weight and subcellular localization patterns

• Optimize experimental conditions:

  • Titrate antibody concentration to determine optimal signal-to-noise ratio

  • Test different blocking solutions (BSA, milk, commercial blockers)

  • Modify washing stringency to reduce background

• Advanced validation techniques:

  • Implement proximity ligation assays for known interacting partners

  • Use sequential ChIP to verify co-occupancy with expected factors

  • Apply CRISPR-based tagging of endogenous SPAC9E9.17c for parallel validation

These approaches build on established antibody validation principles, similar to those used for other challenging targets like IL-17C antibodies and complement components .

How can researchers analyze ChIP-seq data specifically for SPAC9E9.17c to identify biologically relevant interactions?

For optimal ChIP-seq data analysis of SPAC9E9.17c:

• Quality control and preprocessing:

  • Assess sequence quality with FastQC

  • Filter low-quality reads and trim adapters

  • Align to the S. pombe genome (use the most recent assembly)

  • Remove PCR duplicates and filter for uniquely mapped reads

• Peak calling and annotation:

  • Use multiple peak callers (MACS2, HOMER) and focus on consensus peaks

  • Apply appropriate controls (input DNA, IgG ChIP)

  • Compare binding patterns in vegetative vs. quiescent cells

• Integrative analysis:

  • Correlate SPAC9E9.17c binding with histone modifications (H3K4me3, H3K9ac, H2A.Z) known to be associated with active chromatin

  • Examine co-occupancy with RNA polymerase II

  • Compare binding profiles with chromatin remodelers like Ino80C

• Functional analysis:

  • Perform gene ontology analysis of target genes

  • Identify enriched DNA motifs at binding sites

  • Correlate binding with gene expression changes during quiescence

• Visualization and validation:

  • Create genome browser tracks showing binding profiles across conditions

  • Validate selected peaks by ChIP-qPCR

  • Compare with published data on chromatin states in quiescent cells

This analytical approach builds on methodologies used in similar epigenomic studies in S. pombe .

What standardization approaches ensure reproducible results across different batches of SPAC9E9.17c antibody?

To ensure reproducibility across antibody batches:

• Establish robust validation protocols:

  • Create a reference panel of positive and negative control samples

  • Set up quantitative assays to measure antibody performance (ELISA, ChIP-qPCR)

  • Document lot-specific performance metrics including signal-to-noise ratio and sensitivity

• Implement internal controls:

  • Use spike-in controls for normalization (e.g., Drosophila chromatin for ChIP)

  • Maintain reference cell extracts for consistent antibody testing

  • Include standard curves where applicable for quantitative applications

• Record and standardize critical parameters:

  • Document optimal antibody concentration for each application

  • Record buffer compositions and incubation conditions

  • Note any batch-specific optimizations needed

• Cross-validation across methods:

  • Verify antibody performance across multiple techniques (Western blot, ChIP, immunofluorescence)

  • Compare results with orthogonal approaches (RNA-seq, mass spectrometry)

  • When possible, validate findings with epitope-tagged versions of SPAC9E9.17c

These standardization approaches are particularly important for chromatin-associated proteins like SPAC9E9.17c, where subtle variations in antibody performance can significantly impact experimental outcomes .

How should researchers interpret SPAC9E9.17c ChIP-seq profiles in the context of quiescence-specific chromatin remodeling?

When interpreting SPAC9E9.17c ChIP-seq profiles in quiescent cells:

• Compare with chromatin state maps:

  • Overlay SPAC9E9.17c binding with maps of active (H3K4me3, H3K9ac) and repressive (H3K9me2/3) histone modifications

  • Assess correlation with H2A.Z occupancy, which is actively removed by Ino80C during quiescence

  • Examine relationship with RNA polymerase II occupancy patterns

• Consider genomic context:

  • Analyze whether SPAC9E9.17c preferentially associates with subtelomeric regions, which undergo significant remodeling during quiescence

  • Examine binding patterns near genes known to be specifically regulated during quiescence

  • Investigate association with boundary elements that separate heterochromatin from euchromatin

• Temporal dynamics:

  • Analyze time-course data during quiescence entry and exit

  • Identify whether SPAC9E9.17c binding precedes or follows changes in chromatin structure or gene expression

• Genetic dependencies:

  • Compare binding patterns in wild-type versus mutants of chromatin remodeling complexes

  • Assess whether SPAC9E9.17c binding depends on Ino80C or other remodelers

This interpretative framework builds on findings that show dramatic reorganization of chromatin during quiescence, with specific roles for remodeling complexes like Ino80C .

What experimental controls are essential when evaluating SPAC9E9.17c localization in different cellular compartments?

Essential controls for SPAC9E9.17c localization studies:

• Genetic controls:

  • SPAC9E9.17c deletion strain (negative control)

  • Epitope-tagged SPAC9E9.17c strain (parallel positive control)

  • Strains with known nuclear, nucleolar, or cytoplasmic markers

• Antibody controls:

  • Pre-immune serum or isotype-matched control antibody

  • Peptide competition to verify signal specificity

  • Secondary antibody-only controls to assess background

• Cell preparation controls:

  • Synchronized versus asynchronous populations

  • Comparison across growth conditions (vegetative, quiescent, stressed)

  • Fixed versus live cell imaging (where applicable)

• Subcellular fractionation controls (if applicable):

  • Quality control markers for each subcellular fraction

  • Western blot verification of fraction purity using compartment-specific markers

  • Comparison of fractionation results with in situ localization data

• Image analysis controls:

  • Consistent image acquisition parameters across samples

  • Background subtraction and signal normalization

  • Quantification of co-localization with known markers

These controls are essential for unambiguous interpretation of SPAC9E9.17c localization patterns, particularly when examining potential redistribution during quiescence or stress conditions.

What are common issues when using SPAC9E9.17c antibody in fission yeast and how can they be resolved?

Common issues and solutions when working with SPAC9E9.17c antibody:

• Weak or no signal in Western blots:

  • Problem: Insufficient protein extraction or epitope masking

  • Solution: Try different extraction methods (TCA precipitation, alkaline lysis); test alternative blocking agents; consider denaturing conditions that may expose epitopes (similar to iodoacetamide treatment effects observed with anti-C9 antibodies )

• High background in immunofluorescence:

  • Problem: Non-specific binding or autofluorescence

  • Solution: Increase blocking time/concentration; test alternative blocking agents; include detergent (0.1% Triton X-100) in wash buffers; pre-absorb antibody with wild-type yeast extract

• Inconsistent ChIP results:

  • Problem: Variable crosslinking efficiency or chromatin preparation

  • Solution: Optimize formaldehyde concentration and crosslinking time; ensure consistent sonication patterns; implement spike-in controls for normalization

• Poor immunoprecipitation efficiency:

  • Problem: Suboptimal binding conditions or epitope inaccessibility

  • Solution: Test different lysis buffers with varying salt and detergent concentrations; try alternative antibody concentrations; consider native versus crosslinked IP protocols

• Batch-to-batch variability:

  • Problem: Different antibody lots show variable performance

  • Solution: Validate each new lot against reference samples; maintain detailed records of optimization conditions; consider developing monoclonal antibodies for long-term consistency

These troubleshooting approaches are based on general principles of antibody-based techniques and specific challenges observed with yeast proteins and chromatin-associated factors .

How can researchers address non-specific binding issues when using SPAC9E9.17c antibody in complex samples?

To address non-specific binding issues:

• Optimize blocking conditions:

  • Test different blocking agents (BSA, milk, commercial blockers)

  • Increase blocking time or concentration

  • Use species-matched serum in blocking buffer

• Improve washing stringency:

  • Increase salt concentration in wash buffers (from 150 mM to 300-500 mM NaCl)

  • Add detergents (0.1-0.5% Triton X-100 or 0.1% SDS)

  • Perform more extensive washing steps

• Pre-clear samples:

  • Pre-incubate lysates with beads alone before adding antibody

  • Pre-absorb antibody with extracts from knockout strains

  • Use protein A/G beads pre-blocked with BSA or milk

• Improve antibody specificity:

  • Affinity-purify antibody using immobilized antigen

  • Consider using monoclonal antibodies if polyclonal antibodies show high background

  • Test nanobodies or recombinant antibody fragments as alternatives

• Modify sample preparation:

  • Filter lysates to remove aggregates

  • Pre-treat samples with nucleases if DNA/RNA binding contributes to background

  • Use density gradient centrifugation to enrich for specific subcellular fractions